In phase 1b/2 EV-103 Cohort H study neoadjuvant enfortumab vedotin shows excellent pathologic complete response rate of 36,4% in cisplatin-ineligible patients with MIBC. Will it change the landscape of MIBC treatment - time and trials will tell ⏳
https://t.co/DGSC1j97Fq
Highlight ASCO on PEACE-1 trial. Abiraterone acetate 💊 in combination with ADT+docetaxel 🧪improves rPFS up to 2.5 years! New combination approach in routine mCSPC treatment on the horizon!🌅 https://t.co/sp9iwpM3JM
If laser physics seems too complicated, we tried to make it simple 🗿 Thulium fiber laser: an extensive review of basic physics principles. From chromophores to clinical practice. Also, at ESUT soon by @marktaratkin https://t.co/P0Johw0nWo
Placebo effect improves symptoms of chronic prostatitis 💊 Yet to what extent 🤔 ? Our lastest review has the answer - questionnaires are affected, and instrumental tests are not
@AndreyOMorozov@DiBabaevskaya@AK_Bazarkin@Dmitry_Enikeev
https://t.co/WwITz54ajq
🙌Thanks to the 4️⃣0️⃣0️⃣0️⃣ #ICARUS ambassadors and responders who took the @ICARUS_collab Global Assessment Survey
👩⚕️👨⚕️ Surgeons and Anesthesiologist from 3700 Surgical Centers in 135 Countries all over the 🌍
🚨Join the @ICARUS_collab
👉https://t.co/dkE4NwMvUY
Laser en bloc resection is a cutting-edge option in NMIBC treatment❗️
A guide on how to choose the best tool for a job from team of Prof. @Dmitry_Enikeev together with @MarekBabjuk@DrShariat@marktaratkin
@mrsprostate shows the rationale for Focal Therapy in #prostatecancer treatment and the value of identification and target using MRI. See the pre/post treatment changes after HIFU ablation. Proud of sharing the “virtual” floor with her today! @barret_e@Dmitry_Enikeev